EN
HI
Symbiotec Pharmalab Share Price
SYMBIOTEC
1598.66.20 (-0.39%)
NSE
BSE
Free Demat with Zero AMC*
Open a Free Demat Account
+ Free 1st Year AMC
+ Free 1st Year AMC
Summary
As of 21 Nov, 2026, Symbiotec Pharmalab stock price is ₹1598.6. During the trading session, the stock has moved between an intraday low of ₹1588.00 and an intraday high of ₹1654.90. Over the last 52 weeks, Symbiotec Pharmalab has traded between ₹934.20 and ₹1664.90.
The stock has recorded a trading volume of 2,94,589 shares,. Its Average Traded Price (ATP) is ₹1618.38, while the Last Traded Quantity at the Last Traded Price (LTQ@LTP) is 4 @ ₹1598.60.
Symbiotec Pharmalab has an upper circuit limit of ₹1925.70 and a lower circuit limit of ₹1283.90. The total value traded stands at ₹47.68 CR, and the delivery percentage for the day is 34.42%.
The stock is currently traded with a market lot size of 1. Symbiotec Pharmalab also offers a dividend yield of 0%.
Symbiotec Pharmalab Share Price Chart
Symbiotec Pharmalab Share Key Metrics
Volume
2.95 L
Market Cap
10271.98 CR
LTQ@LTP
4@1598.60
ATP
1618.38
Var Margin
16.16 %
Circuit Range
1283.9-1925.7
Delivery %
34.42 %
Value
47.68 CR
ASM/GSM
No
Market Lot
1
Symbiotec Pharmalab Resistance and Support
Pivot 1610.97
Resistance
First Resistance
1637.94
Second Resistance
1671.07
Third Resistance
1698.04
Support
First Support
1577.84
Second Support
1550.87
Third Support
1517.74
Symbiotec Pharmalab Corporate Actions
| Date | Agenda |
|---|---|
| 2026-11-05 | Quarterly Results |
| 2026-09-21 | Quarterly Results |
Symbiotec Pharmalab News
Symbiotec Pharmalab Ltd - 544889 - Announcement Under Regulation 30 (LODR)-Updates (Symbiotec Signs 10-Year Take-Or-Pay Agreement To Manufacture Fermentation-Based Alternative Protein For EU Innovator)
Symbiotec Pharmalab signed a 10-year take-or-pay CDMO agreement with a European alternative protein innovator. Production will take place at the company's Ujjain campus, which includes a new dedicated plant.
Nov 06 2026 09:54:30
Symbiotec Pharmalab Ltd - 544889 - Board Meeting Outcome for Outcome Of The Board Meeting Held Today I.E., Thursday, November 05, 2026, Have Inter Alia Considered And Approved The Unaudited Standalone & Consolidated Financial Results For The Quarter And Half Year Ended September 30, 2026
Symbiotec Pharmalab reported Q2 FY27 cons. revenue of ₹279.93 crores, up 43.2% YoY, and a net profit of ₹51.72 crores, up 169.1% YoY. The company completed its initial public offering and listed its equity shares on September 1, 2026.
Nov 05 2026 19:47:54
Symbiotec Pharmalab Ltd - 544889 - Board Meeting Intimation for Prior Intimation Of The Meeting Of The Board Of Directors Of The Company Is Scheduled To Be Held On Thursday, November 05, 2026
Symbiotec Pharmalab board to meet on November 05, 2026 for financial results.
Oct 28 2026 17:15:29
Read More
Symbiotec Pharmalab Management
| Name | Position |
|---|---|
| Anil Satwani | Chairman & Managing Director |
| Hariharnath Buggana | Nominee Director |
Symbiotec Pharmalab Similar Stocks
Concord Biotech Ltd.
548.20
-8.20 (1.47%)
Metropolis Healthcare Ltd.
567.00
8.30 (1.49%)
Sanofi Consumer Healthcare India Ltd.
3442.40
-52.10 (1.49%)
Akums Drugs & Pharmaceuticals Ltd.
696.20
-16.65 (2.34%)
Yatharth Hospital & Trauma Care Services Ltd.
1094.00
15.50 (1.44%)
Viyash Scientific Ltd.
232.31
-3.53 (1.50%)
Park Medi World Ltd.
238.12
1.04 (0.44%)
Blue Jet Healthcare Ltd.
513.75
-3.10 (0.60%)
Jupiter Life Line Hospitals Ltd.
317.40
36.20 (12.87%)
Aarti Pharmalabs Ltd.
990.70
-33.90 (3.31%)
Symbiotec Pharmalab FAQs
The Buying Price of Symbiotec Pharmalab share is 1598.6 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.
To buy Symbiotec Pharmalab stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Symbiotec Pharmalab, choose your preferred order type, and place the trade.
The Price-to-earnings (P/E) ratio of Symbiotec Pharmalab shares is 93.7. You can compare it with the sector average for relative valuation.
The Price to Book (P/B) ratio Symbiotec Pharmalab shares is 7.57. Useful to assess the stock's value relative to its book value.
To assess Symbiotec Pharmalab’s valuation compare Sector P/E, P/B which are 40.43 & 2.58 with sector averages, along with growth rates and financial metrics.
The Market Cap of Symbiotec Pharmalab is 10271.98 CR. It indicates the company's size category and trading liquidity.
The 52 week high and low prices of Symbiotec Pharmalab share price is 1664.90 & 934.20. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.
Symbiotec Pharmalab belongs to the Healthcare sector.
Open Your Free
Demat Account Now!
AMC for First Year
Auto Square Off Charges
Open a Free Demat Account
+ Free 1st Year AMC
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools

Open Your Free
Demat Account Now!
AMC For First Year
Account Opening Fee
Open a Free Demat Account
+ Free 1st Year AMC
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools
Invest in SYMBIOTEC
Account Opening Fee AMC for 1st Year Auto Square Off Charges Call & Trade
Open a Free Demat Account
+ Free 1st Year AMC
+ Free 1st Year AMC